ArticleFrontiers in immunology2025
Prognostic value of gut microbiota and low-density lipoprotein cholesterol subfractions in patients with ST-segment elevation myocardial infarction.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Gut dysbiosis and the distribution of low-density lipoprotein cholesterol (LDL-C) subfractions have been implicated in cardiovascular risk among patients with ST-segment elevation myocardial infarction (STEMI). However, the prognostic significance of LDL-C subfractions in relation to gut microbiota composition remains largely unexplored. This study aimed to assess differences in gut microbiota profiles and LDL-C subfraction distribution between patients with STEMI with and without major adverse cardiovascular events (MACEs) and to elucidate their potential interplay. Methods: We enrolled 32 male population without coronary heart disease and 66 male patients with STEMI. Fecal samples were analyzed via 16S rDNA gene sequencing to assess gut microbiota diversity and composition. Plasma LDL-C subfractions were quantified using the Quantimetrix Lipoprint LDL System. Results: Among these 66 STEMI patients, 18 experienced MACEs during a median follow-up of 13 months (MACEs group), while 18 age-matched event-free patients were selected as controls (Non-MACEs group). Significant differences in gut microbiota composition, but not diversity, were observed between the two groups, with the Non-MACEs group exhibiting a greater number of marker genera. Although no significant differences were found in LDL-C subfractions between groups, multiple significant negative correlations were identified between gut microbiota and LDL-C subfractions in the MACEs group, including between Conclusion: Gut microbiota, particularly
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.